Using Organs-On-Chips To Evaluate On-Target/Off-Tumor Effects Of Cancer Immunotherapies

Immunotherapy has revolutionized cancer treatment, drawing attention towards safety and effectiveness of these innovative therapies. One of the most promising advancements in this field are T-cell engaging bispecific antibodies (TCBs) that activate T-cells and target cancer cells simultaneously. However, concerns remain over off-target effects. A study, published in eLife and led by Roche and Emulate, introduces Organs-on-Chips as a promising solution. These chips mimic human tissue microenvironments and provide critical insights into TCB efficacy and toxicity.

Discover how lung and intestinal models, validated against primate data, uncover critical insights into antibody affinity, tissue-specific responses, and off-tumor effects. This leap forward promises safer, more effective cancer immunotherapies while reducing reliance on animal testing.